Department of Neurology, Hannover Medical School, Hannover, Germany.
Integrated Research and Treatment Centre Transplantation, Hannover, Germany.
PLoS One. 2019 Aug 23;14(8):e0221626. doi: 10.1371/journal.pone.0221626. eCollection 2019.
In the first weeks after liver transplantation about 30% of the patients develop a posttransplant encephalopathy. A posttransplant encephalopathy comprises metabolic-toxic caused symptoms such as disorientation, confusion, hallucinations, cognitive dysfunction and seizures. We hypothesize that alterations of cerebral metabolites before liver transplantation predispose posttransplant encephalopathy development after liver transplantation.
31 patients with chronic liver disease underwent magnetic resonance spectroscopy (MRS) before liver transplantation to assess glutamine/glutamate (Glx), myo-Inositol (mI), choline (Cho), creatine/phosphocreatine- and N-acetyl-aspartate/N-acetyl-aspartate-glutamate concentrations in the thalamus, lentiform nucleus and white matter. Of these, 14 patients underwent MRS additionally after liver transplantation. Furthermore, 15 patients received MRS only after liver transplantation. Patients' data were compared to 20 healthy age adjusted controls.
Patients showed significantly increased Glx and decreased mI and Cho concentrations compared to controls before liver transplantation (p≤0.01). The MRS values before liver transplantation of patients with posttransplant encephalopathy showed no significant difference compared to patients without posttransplant encephalopathy. Patients after liver transplantation showed increased Glx concentrations (p≤0.01) compared to controls, however, patients with and without posttransplant encephalopathy did not differ. Patients with posttransplant encephalopathy who underwent MRS before and after liver transplantation showed a significant mI increase in all three brain regions (p<0.04) and Glx decrease in the lentiform nucleus after liver transplantation (p = 0.04) while patients without posttransplant encephalopathy only showed a mI increase in the thalamus (p = 0.04).
Patients with and without posttransplant encephalopathy showed no significant difference in cerebral metabolites before liver transplantation. However, the paired sub-analysis indicates that the extent of cerebral metabolite alterations in patients with liver cirrhosis might be critical for the development of posttransplant encephalopathy after liver transplantation.
在肝移植后的最初几周,约 30%的患者会出现肝移植后脑病。肝移植后脑病包括代谢性毒性引起的症状,如定向障碍、意识混乱、幻觉、认知功能障碍和癫痫发作。我们假设肝移植前脑代谢物的改变会导致肝移植后肝移植后脑病的发生。
31 例慢性肝病患者在肝移植前行磁共振波谱(MRS)检查,以评估丘脑、豆状核和白质中谷氨酰胺/谷氨酸(Glx)、肌醇(mI)、胆碱(Cho)、肌酸/磷酸肌酸和 N-乙酰天冬氨酸/N-乙酰天冬氨酸-谷氨酸浓度。其中 14 例患者在肝移植后行 MRS 检查。此外,15 例患者仅在肝移植后行 MRS 检查。将患者的数据与 20 名年龄匹配的健康对照组进行比较。
与对照组相比,患者在肝移植前的 Glx 升高,mI 和 Cho 降低(p≤0.01)。肝移植后发生脑病的患者的 MRS 值与未发生脑病的患者无显著差异。与对照组相比,肝移植后的患者 Glx 浓度升高(p≤0.01),但无脑病和有脑病的患者之间无差异。肝移植后行 MRS 检查的脑病患者在所有三个脑区的 mI 均显著升高(p<0.04),豆状核的 Glx 降低(p=0.04),而无脑病的患者仅在丘脑的 mI 升高(p=0.04)。
有和无肝移植后脑病的患者在肝移植前的脑代谢物无显著差异。然而,配对亚分析表明,肝硬化患者脑代谢物改变的程度可能是肝移植后发生肝移植后脑病的关键。